Understanding the Tumor Immune Microenvironment in Renal Cell Carcinoma

Author:

Shapiro Daniel D.12ORCID,Dolan Brendan1,Laklouk Israa A.3ORCID,Rassi Sahar1ORCID,Lozar Taja4,Emamekhoo Hamid5ORCID,Wentland Andrew L.6,Lubner Meghan G.6,Abel Edwin Jason1ORCID

Affiliation:

1. Department of Urology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA

2. Division of Urology, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA

3. Department of Pathology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA

4. McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA

5. Department of Medical Oncology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA

6. Department of Radiology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53726, USA

Abstract

Scientific understanding of how the immune microenvironment interacts with renal cell carcinoma (RCC) has substantially increased over the last decade as a result of research investigations and applying immunotherapies, which modulate how the immune system targets and eliminates RCC tumor cells. Clinically, immune checkpoint inhibitor therapy (ICI) has revolutionized the treatment of advanced clear cell RCC because of improved outcomes compared to targeted molecular therapies. From an immunologic perspective, RCC is particularly interesting because tumors are known to be highly inflamed, but the mechanisms underlying the inflammation of the tumor immune microenvironment are atypical and not well described. While technological advances in gene sequencing and cellular imaging have enabled precise characterization of RCC immune cell phenotypes, multiple theories have been suggested regarding the functional significance of immune infiltration in RCC progression. The purpose of this review is to describe the general concepts of the anti-tumor immune response and to provide a detailed summary of the current understanding of the immune response to RCC tumor development and progression. This article describes immune cell phenotypes that have been reported in the RCC microenvironment and discusses the application of RCC immunophenotyping to predict response to ICI therapy and patient survival.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference96 articles.

1. (2023, April 05). Seer Cancer Stat Facts: Kidney and Renal Pelvis Cancer. National Cancer Institute: Bethesda, MD, USA, 2022, Available online: https://seer.Cancer.Gov/statfacts/html/kidrp.Html.

2. Cancer statistics, 2022;Siegel;CA A Cancer J. Clin.,2022

3. A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma;Mattila;Sci. Rep.,2021

4. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials;Leibovich;Cancer,2003

5. Overall Survival and Updated Results for Sunitinib Compared with Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma;Motzer;J. Clin. Oncol.,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3